Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia

Leukemia

Volumn 26, Issue 6, 2012, Pages 1266-1276

  Porter, C C ^a   Kim, J ^b,c   Fosmire, S ^a   Gearheart, C M ^a   Van Linden, A ^a   Baturin, D ^a   Zaberezhnyy, V ^b   Patel, P R ^d   Gao, D ^a,c   Tan, A C ^b,c   Degregori, J ^a,b  

^a Nutrition Obesity Research Center at the University of Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Department of Civil and Environmental Engineering at Colorado State University and the Department of Environmental and Occupational Health at the Colorado School of Public Health   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

acute myeloid leukemia; cell cycle; checkpoint; genomics; shRNA screen; WEE1

Indexed keywords

CELL CYCLE PROTEIN; CYTARABINE; PROTEIN WEE1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL CYCLE CHECKPOINT; CELL FATE; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT;

ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CYTARABINE; GENE EXPRESSION PROFILING; GENOME, HUMAN; GENOMICS; HUMANS; LEUKEMIA, MYELOID, ACUTE; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN-TYROSINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; S PHASE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84861999101     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.392     Document Type: Article

References (57)

1. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006; 107: 2099-2107. (Pubitemid 44665642)
2. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011; 29: 551-565.
3. Gilliland DG, Tallman MS. Focus on acute leukemias. Cancer Cell 2002; 1: 417-420. (Pubitemid 41039122)
4. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
5. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249-1259.
6. Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol 2010; 28: 586-595.
7. Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood 2008; 111: 1044-1053. (Pubitemid 351213382)
8. Lowenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011; 364: 1027-1036.
9. Garcia-Carbonero R, Ryan DP, Chabner BA. Cytidine analogs. In: Chabner BA, Longo DL (ed). Cancer Chemotherapy and Biotherapy, Principles and Practice, 3rd edn. Lippincott Williams and Wilkins: Philadelphia, PA, USA, 2001.
10. Kornblau SM, Qiu YH, Bekele BN, Cade JS, Zhou X, Harris D et al. Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected 'survivor cells'. Cell Cycle 2006; 5: 2769-2777. (Pubitemid 44901739)
11. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808-4817.
12. Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T et al. Wnt/Ca2 +NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 2010; 18: 74-87.
13. Huang S, Laoukili J, Epping MT, Koster J, Holzel M, Westerman BA et al. ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 2009; 15: 328-340.
14. Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ et al. Cancer proliferation gene discovery through functional genomics. Science 2008; 319: 620-624. (Pubitemid 351197064)
15. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462: 108-112.
16. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009; 137: 821-834.
17. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 2008; 105: 20380-20385.
18. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009; 137: 835-848.
19. Porter CC, DeGregori J. Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection. Blood 2008; 112: 4466-4474.
20. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010; 26: 139-140.
21. He Z, Zhou J. Empirical evaluation of a new method for calculating signal-to-noise ratio for microarray data analysis. Appl Environ Microbiol 2008; 74: 2957-2966. (Pubitemid 351746997)
22. Rhodes DR, Anstett M. Data processing and normalization. 2010. https://support.oncomine.com (accessed on 4 April 2011).
23. Rhodes DR, Anstett M. Computing fold change. 2010. https://support. oncomine. com (accessed on 4 April 2011).
24. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
25. Li FX, Zhu JW, Hogan CJ, DeGregori J. Defective gene expression, S phase progression, and maturation during hematopoiesis in E2F1/E2F2 mutant mice. Mol Cell Biol 2003; 23: 3607-3622. (Pubitemid 36539193)
26. Saldanha AJ. Java Treeview-extensible visualization of microarray data. Bioinformatics 2004; 20: 3246-3248. (Pubitemid 39619217)
27. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics 2004; 20: 1453-1454. (Pubitemid 38931415)
28. Drexler HG, Quentmeier H, MacLeod RA. Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations. Leukemia 2004; 18: 227-232. (Pubitemid 38247741)
29. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003; 17: 120-124. (Pubitemid 36175896)
30. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006; 124: 1283-1298.
31. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6. (Pubitemid 38391943)
32. Andersson A, Ritz C, Lindgren D, Eden P, Lassen C, Heldrup J et al. Microarraybased classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007; 21: 1198-1203. (Pubitemid 46831808)
33. Stegmaier K, Ross KN, Colavito SA, O'Malley S, Stockwell BR, Golub TR. Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet 2004; 36: 257-263. (Pubitemid 38282750)
34. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350: 1617-1628. (Pubitemid 38528701)
35. Parker LL, Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992; 257: 1955-1957.
36. Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M et al. Smallmolecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009; 8: 2992-3000.
37. Indovina P, Giordano A. Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs. Cancer Biol Ther 2010; 9: 523-525.
38. Banker DE, Groudine M, Willman CL, Norwood T, Appelbaum FR. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents. Leuk Res 1998; 22: 221-239. (Pubitemid 28224660)
39. Vassin VM, Anantha RW, Sokolova E, Kanner S, Borowiec JA. Human RPA phosphorylation by ATR stimulates DNA synthesis and prevents ssDNA accumulation during DNA-replication stress. J Cell Sci 2009; 122 (Part 22): 4070-4080.
40. Fang F, Newport JW. Evidence that the G1-S and G2-M transitions are controlled by different cdc2 proteins in higher eukaryotes. Cell 1991; 66: 731-742. (Pubitemid 121001707)
41. Sebastian B, Kakizuka A, Hunter T. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc Natl Acad Sci USA 1993; 90: 3521-3524. (Pubitemid 23111398)
42. Gu Y, Rosenblatt J, Morgan DO. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J 1992; 11: 3995-4005.
43. Booher RN, Holman PS, Fattaey A. Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity. J Biol Chem 1997; 272: 22300-22306. (Pubitemid 27382865)
44. Holzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010; 142: 218-229.
45. Hattori H, Zhang X, Jia Y, Subramanian KK, Jo H, Loison F et al. RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells. Blood 2007; 110: 640-650. (Pubitemid 47105403)
46. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 2006; 107: 2517-2524. (Pubitemid 43345576)
47. Liejen S, Schellens JH, Shapiro G, Pavlick AC, Tibes R, Demuth T et al. A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol 2010; 28 Abstract: 15s.
48. McGowan CH, Russell P. Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J 1993; 12: 75-85. (Pubitemid 23042384)
49. Kiviharju-af Hallstrom TM, Jaamaa S, Monkkonen M, Peltonen K, Andersson LC, Medema RH et al. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci USA 2007; 104: 7211-7216. (Pubitemid 47186034)
50. Wroble BN, Finkielstein CV, Sible JC. Wee1 kinase alters cyclin E/Cdk2 and promotes apoptosis during the early embryonic development of Xenopus laevis. BMC Dev Biol 2007; 7: 119.
51. Cools T, Iantcheva A, Weimer AK, Boens S, Takahashi N, Maes S et al. The Arabidopsis thaliana checkpoint kinase WEE1 protects against premature vascular differentiation during replication stress. Plant Cell 2011; 23: 1435-1448.
52. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4: 216-225. (Pubitemid 38337501)
53. Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 2004; 3: 305-313. (Pubitemid 41350885)
54. Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010; 9: 514-522.
55. Seliger B, Papadileris S, Vogel D, Hess G, Brendel C, Storkel S et al. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur J Haematol 1996; 57: 230-240. (Pubitemid 26346036)
56. Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A et al. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer 2000; 89: 1976-1982.
57. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993; 82: 2617-2623. (Pubitemid 23318067)